Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A user is exploring making a low-dose topical finasteride solution without minoxidil, using stemoxydine as a vehicle. Others suggest buying from a supplier instead of making it themselves.

The conversation discusses purchasing experimental hair loss treatments KX-826, AHK-Cu, and PTD-DBM, with the user already using Minoxidil and having side effects from Finasteride. Concerns about the legitimacy of certain suppliers and the authenticity of products like pp405 are also mentioned.

Hair loss treatments discussed include finasteride, minoxidil, and dermarolling. Users advise patience, noting initial shedding is common and treatments take time to show results.

The conversation discusses using minoxidil, finasteride, spironolactone, and RU58841 for hair loss treatment. Users share experiences with these treatments, noting side effects and varying effectiveness.

The conversation is about whether stopping Redensyl, unlike Minoxidil, allows you to maintain hair growth benefits. The user is considering Redensyl as an alternative to Minoxidil due to concerns about hair loss upon cessation of Minoxidil.

The user started using oral minoxidil and estradiol in August 2025, added finasteride in December, and experienced significant hair shedding in February/March. They switched to estradiol injections and are considering their hair washing routine, while another user suggested consulting a dermatologist and possibly trying dutasteride.

The conversation discusses using GFM Gel, a topical gel with polypeptides that mimic growth factors to promote hair regrowth and strengthen hair. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.

The post discusses diluting 100ml of 0.1% topical finasteride with 90ml of stemoxydine to create a 0.05% solution, aiming for a longer-lasting and potentially less side-effect-prone treatment. The user seeks feedback on this idea.

Upcoming hair loss treatments for those who can't tolerate DHT blockers, focusing on Minoxidil, microneedling, and ketoconazole. Promising treatments include GT20029, PP405, KX-826, and RU58841, though RU58841 may not be safe.

The user has been using finasteride for 10 months, experiencing continuous shedding since month 3, and is also using minoxidil, derma stamping, and keto shampoo. They are concerned about hair density loss and seeking advice on whether to continue finasteride.

The conversation discusses using nandrolone decanoate as a replacement for testosterone to potentially regrow hair, with OP considering stopping finasteride and testosterone replacement therapy (TRT) to try nandrolone solo. Concerns include maintaining estradiol levels, and some users report mixed results with hair regrowth using this approach.

PP405 is being discussed as a potential treatment for hair loss, with uncertainty about its effectiveness compared to existing treatments like finasteride, dutasteride, and minoxidil. There is cautious optimism, but its impact on hair transplants remains unclear.

The conversation discusses the use of Verteporfin in treating hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. PP405 is still under evaluation for safety.

Pyrilutamide is believed to be more effective than RU58841 and 1 mg finasteride in treating hair loss, with no systemic hormonal effects and the potential to block more than 31% of scalp DHT. It may also antagonize scalp testosterone due to its action as an androgen receptor antagonist.

The conversation is about creating a topical finasteride solution without minoxidil, using an alcohol-based base like ethanol. The discussion includes using finasteride in powder form and mentions adding ingredients like glycerol, salicylic acid, or castor oil.

Delayed release oral minoxidil is seen as a promising advancement for hair loss treatment, offering safer, higher doses and more consistent hair follicle stimulation compared to current options. However, it is not expected to replace finasteride or dutasteride, as it does not prevent androgenetic alopecia.

CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.

Promising hair loss treatments in 2026 include GT20029, a topical androgen receptor degrader, and VDPHL01, an extended-release oral minoxidil, both offering safer alternatives with fewer side effects. Other treatments like sublingual minoxidil, OND-1, JW0061, TDM-105795, and AMP-303 are also being explored.

A user is trying to make a topical finasteride solution by crushing tablets into ethanol and glycerin but struggles with spillage. Suggestions include letting the tablets dissolve in the solution or using a pill crusher for efficiency.

The user plans to use 1% Koshine826, 0.1% Alfatradiol, Minoxidil with Tretinoin, microneedling, and Stemoxydine for hair loss treatment. They expect significant recovery with this regimen.

The conversation discusses a hair loss treatment regimen involving minoxidil, finasteride, RU58841, JXL069, and nizoral shampoo. The user reports seeing new black dots in areas where hair hasn't grown in years, suggesting potential regrowth.

Mixing 1ml of topical Minoxidil and Pyrilutamide (2ml total) together in a container and applying immediately is being discussed. The concern is whether this method degrades or compromises the efficacy of either compound.

The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.

PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.

PP405 may revive dormant hair follicles but is unlikely to help with long-term baldness where follicles are replaced by scar tissue. It is seen as a potential adjunct to treatments like minoxidil and finasteride, but its effectiveness on deeply fibrotic or scarred areas is doubtful.

Mango oil may inhibit DKK1 and DHT, potentially aiding hair growth by activating the Wnt signaling pathway. A user plans to test mango leaves juice and other Ayurvedic products for hair regrowth.

New hair loss treatments, including Breezula, VDPHL01, and PP405, are nearing Phase 3 trials, offering hope for effective solutions. Current treatments like finasteride and minoxidil remain effective, but early intervention is crucial.

A 25-year-old male with androgenetic alopecia experienced improved hair condition after using finasteride, oral minoxidil, and dutasteride, but later faced diffuse thinning and texture deterioration after a shedding phase. Others suggest patience, continued treatment, and using ketoconazole shampoo, with some sharing similar experiences of post-shed thinning.